Filing Flows › TG Therapeutics (TGTX) › Q3 2026
TG Therapeutics (TGTX) Q3 2026 earnings results (third quarter 2026)
8-K filed Nov 9, 2026
TG Therapeutics (TGTX) reported revenue of $260M for the third quarter 2026 (Q3 2026), +61% from a year earlier and +8% from the quarter before. Operating margin was 33.0%, net earnings $55.5M (21.3% of revenue).
TG Therapeutics, Q3 2026: revenue $260M (+61% year over year), operating margin 33.0%, net earnings $55.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $260M | +8% | +61% |
| Operating profit | $85.9M | +296% | +193% |
| Net earnings | $55.5M | +613% | -86% |
What changed
Revenue was $259.9M in Q3 2026, up 61% year over year and up 8% from the previous quarter. Product revenue, net was the largest line at 92% of revenue. Product revenue, net added $80.7M year over year (up 51%), 82% of the total change.
Operating profit was $85.9M, a 33.0% margin (up 14.9 points year over year). Of the extra revenue versus Q3 2025, 58% reached operating profit, above the 18% margin then. Total costs grew 32% against revenue growth of 61%. The fastest-growing cost line was Cost of revenue (+50%). Net earnings were $55.5M, down 86% year over year. The effective tax rate was 24.9%.
Questions
What was TG Therapeutics' revenue in the third quarter 2026?
TG Therapeutics (TGTX) reported revenue of $260M for the third quarter 2026 (Q3 2026), +61% from a year earlier and +8% from the quarter before.
Was TG Therapeutics profitable in the third quarter 2026?
Operating profit was $85.9M (33.0% of revenue) and net earnings $55.5M.
Source: TG Therapeutics 8-K on SEC EDGAR.